2023-509055-14-00招募中2 期
Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation (alloSCT) In Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Neoplasia (HR-MDS) with IDH1 Mutation (PIVOT)
Technische Universitat Dresden14 个研究点 分布在 1 个国家目标入组 76 人开始时间: 2025年4月11日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 76
- 试验地点
- 14
- 主要终点
- Rate of event-free survival (EFS) at two years after study inclusion. Events are defined as death from any cause or disease relapse defined as reappearance of leukemic blasts in peripheral blood or ≥ 5% bone marrow blasts or development of extramedullary disease as defined according to 1 or end of or initiation of any new anti-cancer therapy.
研究概览
简要总结
Main objective it to evaluate the efficacy of Ivosidenib (investigational drug) to improve event-free survival in patients with AML or MDS carrying an IDH1 mutation when given as 24 months maintenance therapy following allo SCT.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Age ≥ 18 years
- •Negative serum pregnancy test
- •Male subjects must agree to refrain from unprotected sex and sperm donation from time point of signing the informed consent until 1 month after the last dose of the investigational medicinal product
- •Willingness and ability to comply with all study procedures
- •Informed consent signed by the patient capable of giving
- •Eastern Cooperative Group (ECOG) performance status ≤
- •AML or MDS according to WHO criteria with IDH1 mutation
- •having received alloSCT within the past 100 days
- •documented CR, CRi, CRh or MLFS after alloSCT within 28 days prior to enrolment (documented by bone marrow aspiration)
- •Adequate organ function defined by: Serum creatinine clearance > 30 mL/min; calculated by the Cockcroft Gault formula
- •Adequate organ function defined by: Serum total bilirubin ≤2 × ULN, unless considered to be due to Gilbert’s disease
- •Adequate organ function defined by: Left ventricular ejection fraction (LVEF) ≥ 35%
排除标准
- •Active acute GvHD grade III-IV according to Harris criteria requiring steroids > 1 mg/kg prednisolone equivalent
- •Indications that the subject is unlikely to adhere to the protocol (e.g., lack of compliance)
- •Substance abuse, medical, psychological, or social conditions that may interfere with the subject’s cooperation with the requirements of the trial or evaluation of the study results
- •Significant cardiac disease: i.e., heart failure NYHA III or IV; unstable angina pectoris; recent myocardial infarction or clinically significant bradycardia
- •Long QT syndrome (QTcF ≥480 msec on screening ECG)
- •Concurrent use of medications that have a relative risk of prolonging QT interval or of inducing Torsade de Pointes unless it is secured that if patient receive medications with known QT interval prolonging potential concomitantly, ECG monitoring has to be conducted weekly, or more frequently based on institutional standards or investigator discretion for the first 3 weeks following initiation of Ivosidenib treatment
- •Pulmonary disease with clinically relevant hypoxia (need for oxygen inhalation)
- •Patients undergoing renal dialysis
- •Active severe or uncontrolled infection
- •Any condition that limits the ingestion or gastrointestinal absorption of orally administered drugs
- •Diagnosis of another primary malignancy that is currently clinically significant or currently requires active treatment / intervention
- •Hypersensitivity known from medical history to Ivosidenib or its ingredients or to drugs with a similar chemical structure
- •Concomitant administration of dabigatran and/or a familial history of sudden death or polymorphic ventricular arrhythmia and/or the rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption
- •Having received any unlicensed drug within 30 days or 5 half-lives, whichever is greater, prior to enrolment
- •Addictions or other illnesses that do not allow the patient concerned to assess the nature and extent of the clinical trial and its possible consequences
- •Pregnant or breastfeeding women, breastfeeding has to be discontinued before onset of treatment and until for at least 1 month after the last dose
- •Patients who are unwilling to follow strictly highly effective contraception requirements including hormonal contraceptives with a Pearl Index < 1% per year in combination with a barrier method from time point of signing the informed consent until 1 month after the last dose of the IMP unless one of the following criteria is met: post-menopausal (12 months natural amenorrhoea or 6 months amenorrhoea with serum FSH > 40 U/ml)
- •Patients who are unwilling to follow strictly highly effective contraception requirements including hormonal contraceptives with a Pearl Index < 1% per year in combination with a barrier method from time point of signing the informed consent until 1 month after the last dose of the IMP unless one of the following criteria is met: postoperative (6 weeks after bilateral ovariectomy with or without hysterectomy)
- •Patients who are unwilling to follow strictly highly effective contraception requirements including hormonal contraceptives with a Pearl Index < 1% per year in combination with a barrier method from time point of signing the informed consent until 1 month after the last dose of the IMP unless one of the following criteria is met: medically confirmed ovarian failure
- •Patients who are unwilling to follow strictly highly effective contraception requirements including hormonal contraceptives with a Pearl Index < 1% per year in combination with a barrier method from time point of signing the informed consent until 1 month after the last dose of the IMP unless one of the following criteria is met: vasectomy of the partner
结局指标
主要结局
Rate of event-free survival (EFS) at two years after study inclusion. Events are defined as death from any cause or disease relapse defined as reappearance of leukemic blasts in peripheral blood or ≥ 5% bone marrow blasts or development of extramedullary disease as defined according to 1 or end of or initiation of any new anti-cancer therapy.
Rate of event-free survival (EFS) at two years after study inclusion. Events are defined as death from any cause or disease relapse defined as reappearance of leukemic blasts in peripheral blood or ≥ 5% bone marrow blasts or development of extramedullary disease as defined according to 1 or end of or initiation of any new anti-cancer therapy.
次要结局
- Rate of overall survival (OS) at two years after study inclusion (written informed consent).
- EFS and OS as time-to-event analysis including follow-up.
- Rate of complete molecular remissions (CRMRD-) as defined by international consensus guidelines at 6, 12 and 24 months after study inclusion.
- MRD conversion rate from positive (CRMRD+) to negative (CRMRD−) as defined by international consensus guidelines among subjects with measurable residual disease at baseline.
- Cumulative incidence of higher grade acute GvHD defined as new onset of or increase in severity to grade III-IV aGVHD as defined by investigator following international expert consensus guidelines .
- Cumulative incidence and maximal grade (according to international expert consensus guidelines) of chronic GvHD requiring systemic treatment within one year after alloSCT.
- Cumulative incidence of AEs/SAEs Grade ≥3 or leading to dose reduction/discontinuation of study treatment.
- Cumulative incidences of non-relapse mortality within 100 days and 2 years from study inclusion defined as death that was not proceeded by recurrent or progressive malignancy.
- Cumulative incidence of relapse mortality within 2 years from study inclusion.
- Number of patients who require dose reductions or have to stop study treatment due to toxicity reasons.
研究者
Dr. med. Jan Moritz Middeke
Scientific
Technische Universitat Dresden
研究点 (14)
Loading locations...
相似试验
招募中
2 期
Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 CholangiocarcinomaCholangiocarcinomaCholangiocarcinomaNCT07260175Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest40
招募中
3 期
Vorasidenib for the treatment of IDH-mutant astrocytoma after standard chemoradiotherapy2024-519404-27-00Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi247
尚未招募
2/3 期
adIVO2024-520219-42-00Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH40
招募中
1 期
A Phase IB Study to determine efficacy and safety of Durvalumab and/or novel anti-cancer agents, with or without chemotherapy, in patients with previously untreated NSCLC2024-511956-42-00AstraZeneca AB44
进行中（未招募）
3 期
一项在携带 IDH1 或 IDH2 突变的残留或复发性 2 级胶质瘤亚洲受试者中开展的 Vorasidenib（S095032/AG881）的 III 期研究CTR2024258155